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Background: Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disorder characterized by
diabetes mellitus (DM), optic atrophy (OA), central diabetes insipidus (CDI) and deafness (D).
The phenotype of the disease has been associated with several mutations in the WFS1 gene, a nuclear gene
localized on chromosome 4. Since the discovery of the association between WFS1 gene and Wolfram syndrome,
more than 150 mutations have been identified in WS patients.
We previously described the first case of perinatal onset of Wolfram syndrome newborn carrying a segmental
uniparental heterodysomy affecting the short arm of chromosome 4 responsible for a significant reduction in
wolframin expression.
Here we review and discuss the pathophysiological mechanisms that we believe responsible for the perinatal onset
of Wolfram syndrome as these data strongly suggest a role for WFS1 gene in foetal and neonatal
neurodevelopment.
Case presentation: We described a male patient of 30 weeks’ gestation with intrauterine growth restriction and
poly-hydramnios.
During the first days of life, the patient showed a 19% weight loss associated with polyuria and hypernatremia. The
presence of persistent hypernatremia (serum sodium 150 mEq/L), high plasma osmolarity (322 mOsm/L) and low
urine osmolarity (190 mOsm/l) with a Uosm/Posm ratio < 1 were consistent with CDI. The diagnosis of CDI was
confirmed by the desmopressin test and the brain magnetic resonance imaging (MRI) at 34 weeks of age, that
showed the lack of posterior pituitary hyperintense signal. In addition, a bilateral asymmetrical optic nerve hypoplasia
associated with right orbital bone hypoplasia was observed, suggesting the diagnosis of WF.
During the five years follow-up the patient did not developed glucose intolerance or diabetes mellitus. By the end of
the second year of life, primary non-autoimmune central hypothyroidism and mild neurodevelopment retardation were
diagnosed.
Conclusions: The analysis of our case, in the light of the most recent literature, suggests a possible role for WFS1 gene
in the development of certain brain structures during the fetal period.
Wolfram syndrome should be considered in the differential diagnosis of the rare cases of congenital central diabetes
insipidus developed in the neonatal period.* Correspondence: stefano.ghirardello@mangiagalli.it
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Wolfram syndrome (WS1) (MIM #222300), first described
by Wolfram and Wagener in 1938 [1], is a rare autosomal
recessive neurodegenerative disorder with an estimated
prevalence of 1: 770.000 live births and a carrier frequency
of 1: 354 [2,3]. It is also known by the acronym DIDMOAD
in order to include four characteristic clinical abnormalities:
central diabetes insipidus (DI), diabetes mellitus (DM),
optic atrophy (OA) and deafness (D).
The diagnosis of Wolfram syndrome is based on the
presence of the two minimal diagnostic criteria: early
onset DM (<15 years) and bilateral progressive OA. DM
is usually the first symptom to present at a median age
of 6 years, followed by the onset of OA at a median age
of 11 years. The incidence of central DI varies consider-
ably, ranging from 48% to 78%, as generally it does not
appear until the 2nd or 3rd decade and, initially, it may
be partial. Frequently, sensorineural deafness develops at
an average age of 16 years (range 4–39 years). A wide
spectrum of abnormalities of the endocrine glands, the
central nervous system (CNS) and the urogenital tract has
been described, comprising hypothyroidism, hypogonad-
ism and ACTH deficiency, anosmia, ataxia, seizures, nys-
tagmus, gaze palsies, dysarthria, dysphagia, psychiatric
disorders, cognitive deficits, hypo or areflexia and neuro-
genic bladder, central sleep apnea, neurogenic upper air-
way collapse, myoclonus, Parinaud’s syndrome [3-7]. The
leading cause of death, that typically occurs around the
age of 30 (range 25–50), is the central respiratory failure
resulting from brainsteam atrophy [7].
The disease phenotype has been associated to muta-
tions in WFS1, a nuclear gene mapped on chromosome
4p16.1, encoding for the endoglycosidase membrane
glycoprotein named wolframin. Wolframin plays a pro-
tective function against endoplasmic reticulum (ER)
stress and it is involved in calcium storage, redox regula-
tion, steroid synthesis, and cell death [8-12]. Acquired or
inherited ER dysfunction can cause rare genetic diseases
as well as common chronic diseases, including DM and
neurodegenerative diseases [13-16].
Since the discovery of the association between WFS1
gene and Wolfram syndrome, more than 150 mutations
have been identified in WS patients. However, no evident
genotype-phenotype correlations were found [7].
We recently described the first case of Wolfram syn-
drome perinatal onset, presenting with congenital OA and
CDI, in a growth-restricted male infant, born at 30 weeks
gestation,. A detailed description of the underlying genetic
defect, a segmental uniparental heterodysomy affecting
the short arm of chromosome 4 responsible for the signifi-
cant reduction in wolframin expression, have been previ-
ously published [16].
Here we review the pathophysiological mechanisms
possibly responsible for the perinatal onset of Wolframsyndrome according to the recent published evidence of
WFS1 role in fetal and neonatal neurodevelopment.
Case report
We described a male patient, born to a 38 years old mother
at 30 weeks’ gestation by emergency Cesarean section, per-
formed because of pre-eclampsia and IUGR associated
with poly-hydramnios, detected by 26 weeks. The preg-
nancy was complicated by maternal type 2 DM, requiring
subcutaneous insulin, Antenatal serologies (TORCH, HIV,
Treponema and Hepatitis) were protective. Cytogenetic
investigation of the fetus by villocentesis confirmed a nor-
mal 46,XY karyotype. Paternal medical history was unre-
markable. Parents were non-consanguineous Caucasians.
Apgar scores were 6 at 1 minute and 7 at 5 minutes of
life. Physical parameters were as follows: weight 1190 g
(<10° centile), length 36 cm (<3° centile) and head cir-
cumference 26 cm (<10° centile). Physical examination
was normal except for a moderate respiratory distress,
During the first hours of life, the respiratory status wors-
ened, evolving towards a third-degree hyaline-membrane
disease that required surfactant administration, mechan-
ical ventilation for a 24 hour period and non-invasive
ventilation for 10 days.
Throughout the first 3 days of life, the patient experi-
enced a significant weight loss (as high as 19% of the
birth weight), associated with polyuria (4.7-5.5 ml/kg/h)
and hypernatremia (serum sodium 152–159 mEq/l), des-
pite adequate fluid intake. At first, hypernatremia was
interpreted as a consequence of the excessive weight loss
and treated with large amounts of daily intravenous
fluids (180–200 ml/kg/d). The clinical course was compli-
cated by one episode of Serratia Marcescens septic shock
during the second week of life and disseminated intravas-
cular coagulation requiring plasma administration, platelet
transfusion and aggressive antibiotic therapy.
CDI was subsequently suspected as a result of persist-
ent hypernatremia (serum sodium 150 mEq/L), high
plasma osmolarity (322 mOsm/L) and low urine osmo-
larity (190 mOsm/l) with a Uosm/Posm ratio < 1 associ-
ated with failure to thrive during the first four weeks of
life. The diagnosis of CDI was confirmed by the desmo-
pressin test, showing a normal urine concentrating cap-
ability after nasal desmopressin (DDAVP) administration
with rapid raise in urine osmolarity and reduced plasma
osmolarity and the brain MRI at 34 weeks postmestrual
age demonstrating the lack of posterior pituitary hyper-
intense signal. Bilateral asymmetrical optic nerve hypo-
plasia associated with right orbital bone hypoplasia was
also observed, suggesting the diagnosis of WF [17]. No
other abnormalities of the CNS were found.
Ophthalmologic examination revealed eyeball and right
optic disc hypoplasia, associated with exotropia. Visual
evoked potential confirmed the pathological findings of
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sulted normal. Audiological examinations were normal.
Borderline TSH values with normal thyroid function were
recorded during hospitalization, but no treatment was
required until the end of the first year of life, when levo-
thyroxine substitutive therapy was started because of pri-
mary non-autoimmune central hypothyroidism with a
small thyroid gland. During the five years follow-up mild
psychomotor and mental retardation were diagnosed. No
glucose intolerance or diabetes mellitus have been de-
tected so far.
After the catch-up growth, length and head circumfer-
ence has stabilized around the 50° centile and, after the
first year of life, body weight was above the 97° centile.
Water and electrolyte balance is maintained with stand-
ard doses of nasal desmopressin.
No progression of the bilateral asymmetrical OA was
noted at the 1-year follow-up MRI. However, new patho-
logical signs (reduced corpus callosus, moderate ventricular
dilatation, asymmetric hippocampus and altered occipital
peri-ventricular white matter signal intensity) [17] were
noticed.
Genetic investigation of the patient and his relatives re-
vealed a segmental paternal heterodisomy of the chromo-
some 4 (segmental pat-hUPD4), involving at least part of
the promoter and the first exon ofWFS1 that we hypothe-
sized could remove splicing regulatory motifs located in
intron 1. Direct sequencing analysis of WFS1 cDNA
showed a mixed sequencing pattern including the wild-
type transcript sequence and two splice variants. The first
splice variant was a previously described 4-bp deletion in
exon 2, while the second one exhibited the complete skip-
ping of exon 2 and, probably, the loss of the transcription
start site. RT-PCR confirmed a normal mRNA expression
compared to young controls, while Western blot ana-
lysis showed a significantly decreased Wolframin ex-
pression [17]. Informed consent for genetic studies was
obtained from all subjects involved in the study.
Discussion
In this report we deepened from the clinical point of
view the case of an atypical Wolfram patient, presenting
during fetal and neonatal life. As a matter of fact, we dis-
covered DI and OA during the examination performed
after the delivery, that occurred long before the term of
pregnancy, albeit the antenatal origin of the CDI was
suggested by poly-hydramnios, polyuria and rapid body-
weight loss occurred since first days of postnatal life. In
addition, we speculate that the OA and the hypoplasia of
the eyeball were caused by a pathological process origin-
ating during fetal life.
The Wolfram syndrome is caused by mutations of the
protein Wolframin, essential for the regulation of intra-
cellular calcium homeostasis, the cell cycle progressionand the retrieval of homeostasis under conditions such
as ER stress [10-12]. Indeed, WFS1 is a key element of
the ER stress activated signalling cascade, also known as
unfolded protein response (UPR). In particular, WFS1
regulates ATF6A activity, one of the ER stress-sensor
molecules that induces UPR target genes and prevents
cells from apoptosis caused by the imbalance between
productive folding of secretory proteins and degradation
of misfolded proteins [11,13] (Figure 1).
The ER environment can be disrupted by both, physio-
logical (i.e. post-prandial insulin biosynthesis that increases
the workload of the ER) and pathological (i.e. hypoxia,
hypoglycaemia or mutated proteins) processes, causing the
production of toxins, cytokines and mutant proteins ex-
pression [13,18,19].
Patients affected by Wolfram syndrome exhibit a dys-
regulated ER stress signaling. The uncontrolled ATF6α
up-regulation determines apoptosis of sensitive cell types,
in particular pancreatic β cells and neural cells [12,13].
Recent insight arising from animal studies led to the
conclusion that Wolframin may also be essential for the
processing of the arginine vasopressin (AVP)-precursor
and for the survival of the supraoptic (SO) and the sup-
raventricular hypothalamic (PV) nuclei neurons [20].
Gabreel and colleagues demonstrated the abnormal pro-
cessing of AVP-precursor in the SO and PV nuclei and
the presence of reactive gliosis in human tissues recov-
ered during the autopsy of patients with longstanding
CDI. On the contrary, no gliosis was detected in patients
that were symptomatic for a shorter period of time, sug-
gesting that the pathogenesis of CDI in Wolfram patients
is characterized by a progressive three-step phase process:
1) a down-regulation of the amount of processed AVP and
partial CDI, 2) a complete disappearing of processed AVP,
and 3) a complete disappearance of AVP-producing cells
in the hypothalamic nucleus [21].
Investigations in our patient did not allow neither to
determine the mechanisms underlying the development
of early onset CDI, nor to correlate his rare and previ-
ously undescribed mutation to his unique phenotype
[17]. The most likely explanation is a specific and severe
prenatal/postnatal ER workload in the SO and PVN, that
led to a rapid neuronal dysfunction and/or death due to
a very low Wolframin level. We speculated that the
underlying mechanisms were the rising production of
AVP during the second trimester of pregnancy (increase
of over 1000 times), the active role of fetal vasopressin
in the birth process and the redistribution of the fetal
blood flow, contributing to stress adaptation [22]. More-
over, mechanical ventilation and septic shock are known
to increase the production of vasopressin, as demon-
strated in plasma and urine samples of newborns who
received neonatal intensive cares [23,24]. Not to be for-
gotten that the oxidative stress secondary to pregnancy
Figure 1 WFS1 is a key element of the ER stress activated signalling cascade, called the unfolded protein response (UPR). WFS1
regulates ATF6 protein through the ubiquitin-proteasone pathway, stabilizing and enhancing the function of its E3 ligase, HRD1 and acts as a
negative regulator of this pathway. The E3 ubiquitin ligase HRD1 is found in the endoplasmic reticulum membrane and is involved in endoplasmic
reticulum-associated degradation. In response to ER stress, the cleaved form of ATF6 translocates to the nucleus. The non-cleaved form of ATF6 is
degraded by the ubiquitin-proteasome pathway to prevent the hyperactivation of the UPR.
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diabetes and growth-restriction) lead to lipid peroxidation,
protein and DNA damage, both in the mother and the
fetus. These mechanisms may have contributed to the ER
overload and, finally, to the apoptosis or the premature
cellular senescence [25,26].
WFS1 expression has been fully characterized in the
murine CNS. Wolframin presence has been confirmed
in several CNS structures, comprising the amigdala, the
hippocampal region, the hypothalamic magnocellular
neurosecretory system, the brainstem nuclei, the globus
pallidus, and the posterior caudate putamen [20,27]. Hilson
and colleagues demonstrated that Wolfram patients exhib-
ited abnormalities in various brain regions, including hypo-
thalamus, pituitary, pons, inferior olivary nucleus, lateral
geniculate nucleus, thalamus, cerebellum and optic nerve
and optic tract [28].
The neuroimaging evolution of our patient at 1 year
of life showed new pathological features such as re-
duced corpus callosus, moderate ventricular enlarge-
ment, asymmetric hippocampus and altered occipital
peri-ventricular white matter signal. This suggests a
neurodegenerative process affecting brain structures,
known to be damaged by the loss of WFS1, but even
more widely the white and gray matter. However, we
can not exclude that the radiological findings as well
as the mild psychomotor and mental retardation may
be a consequence of prematurity and co-morbidities;
In fact, disabilities affect roughly 30% of patients born
between 29 and 32 weeks of gestational age andseptic shock is an established cause of white matter
damage [29,30].
The bilateral asymmetrical OA associated with the
eyeball hypoplasia and the right orbital bone hypoplasia
were evident by the first month of life, suggesting an al-
teration in the development rather than an involution of
optic nerves.
In control mice, Wolframin is expressed in neurons
and glial cells of the optic nerve, the SC, the SCN and
the visual cortex, while in the retina it was expressed in
all neuron subtypes [31]. In humans, it was found that
Wolframin is abundant in retinal ganglion cells (RGCs),
cell bodies and initial portion of axons, so RGCs could
be affected by Wolframin disfunction both at level of the
cell body or of the unmyelinated portion of the optic
nerve. Such defect could lead to axonal transport deficits
and/or perturbations of important cell functions, thus
causing OA. Besides, the presence of wolframin in the
optic nerve astrocytes suggests that WFS1 mutations may
affect their ability to provide nutrients to optic axons
when they suffer from ER dysfunction [32].
In our patient, the presence of optic nerve hypoplasia
with orbital bone hypoplasia long before term corrected
age allowed new speculations about the underlying patho-
genetic mechanisms, supported by recently published
work. The vast majority of the critical processes involved
in the retinal development occur between 24 weeks gesta-
tion and 3 to 4 months of postnatal life, while the axonal
development of the optic tract occurs between 20–30
weeks of gestation [33]. A recent study by the Washington
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cranial volume, mainly due to reduced brainstem, cerebel-
lum and optic radiation volume, starting from the earliest
stages of the disease in Wolfram patients as compared
to healthy controls and type 1 diabetic patients, [34],
Such findings were considered more severe than neu-
robehavioural findings tested in their cohort of pa-
tients. The authors’ conclusions stated that these brain
abnormalities exacerbated by a neurodegenerative process,
originally result from a neurodevelopmental disruption
dating back to the early stages of the CNS development.
Similar conclusions were drawn thanks to post-mortem
examination of Wolfram patients, as a discrepancy be-
tween the atrophic component of some brain regions
(pons and medulla) and the neuronal loss was docu-
mented [28].
Heterozygous missense mutations in WFS1 have been
linked to autosomal dominant low frequency neurosen-
sory hearing impairment and psychiatric disorders [35].
Eight families with OA and deafness carrying a single, re-
current heterozygous missense mutation in WFS1 gene
leading to reduced levels of mutant wolframin have been
described [36]. More recently, Chaussenot et al. described a
cohort of 96 Wolfram patients with a wide spectrum of
phenotypes. In particular, about 14% of the patients
showed late-onset symptoms (after 15 years of life) and
one patient (WS9), affected by IUGR, cataract and psy-
chomotor delay developed OA and hearing impairment
by 6 months of life. Type 2 Wolfram syndrome, caused by
mutations of the CISD2 gene on the chromosome 4q22,
has been diagnosed in three large Jordanian families. The
phenotype is similar to the type 1- syndrome although
diabetes insipidus has not been described [37,38]. These
reports underline our incomplete knowledge of wolframin
functions.
Conclusion
The analysis of our case reinforces the intriguing hypothesis
that the WFS1 plays a role in the development of
neural structures, such as the optic nerve and the neuro-
hypophyseal tract. After a careful examination of the pa-
tient and the extensive review of the literature, we speculate
that this early and severe OA cannot be entirely explained
by a progressive degenerative mechanism, although further
studies are needed in order to identify all cerebral struc-
tures expressing Wolframin during embryogenesis and fully
elucidate its role in the neurodevelopment.
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